Summary

This article discusses the results of a correlative study in the Phase 3 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma trial [Radiation Therapy Oncology Group (RTOG) 0825; NCT00884741; Sulman EP et al. J Clin Oncol 2013 (suppl; abstr LBA2010)]. The study examined the molecular predictors of outcome and response to bevacizumab (BEV) added to standard chemoradiation for patients with newly diagnosed gliobastoma. The study aimed to identify patients likely to respond to BEV during initial treatment for glioblastoma using a gene biomarker detectable in formalin-fixed, paraffin-embedded tissue.